Value of perfusion CT parameters, Microv essel density and VEGF expression in differentiation of benign and malignant prostate tumours

Polish Journal of Pathology

Volumn 65, Issue 3, 2014, Pages 229-236

  Luczynska, Elzbieta ^a   Gasinska, Anna ^a   Blecharz, Pawel ^a   Stelmach, Andrzej ^a   Jereczek Fossa, Barbara Alicja ^b,c   Reinfuss, Marian ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Microvessels; Perfusion computed tomography; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; AREA UNDER THE CURVE; BIOSYNTHESIS; CANCER GRADING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MICROVASCULATURE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; VASCULARIZATION;

AGED; AREA UNDER CURVE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSELS; MIDDLE AGED; NEOPLASM GRADING; NEOVASCULARIZATION, PATHOLOGIC; PERFUSION IMAGING; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908097019     PISSN: 12339687     EISSN: 20849869     Source Type: Journal    
DOI: 10.5114/pjp.2014.45787     Document Type: Article

References (30)

1. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004; 171 (6 Pt 1): 2221-2225.
2. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
3. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.
4. Sotomayor P, Godoy A, Smith GJ, Huss WJ. Oct4 A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009; 69: 401-410.
5. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536-542.
6. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253-270.
7. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-2261.
8. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001; 35: 437-452.
9. de la Taille A, Katz AE, Bagiella E, et al. Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD 31. Am J Clin Pathol 2000; 113: 555-562.
10. Stefanou D, Batistatou A, Kamina S, et al. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo 2004; 18: 155-160.
11. Longo R, Sarmiento R, Fanelli M, et al. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002; 5: 237-256.
12. Russo G, Mischi M, Scheepens W, et al. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int 2012; 110 (11 Pt C): E794-808.
13. Petralia G, Bonello L, Viotti S, et al. CT perfusion in oncology: how to do it. Cancer Imaging 2010; 10: 8-19.
14. Bellomi M, Viotti S, Preda L, et al. Perfusion CT in solid body-tumours. Part II: Clinical applications and future development. Radiol Med 2010; 115: 858-874.
15. Osimani M, Bellini D, Di Cristofano C, et al. Perfusion MDCT of prostate cancer: correlation of perfusion CT parameters and immunohistochemical markers of angiogenesis. AJR Am J Roentgenol 2012; 199: 1042-1048.
16. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 2002; 111: 58-64.
17. Edition S. Cancer Staging Manual. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, et al. (eds.). Cancer 2010; 20-22.
18. Petralia G, Preda L, D’Andrea G, et al. CT perfusion in solid- body tumours. Part I: Technical issues. Radiol Med 2010; 115: 843-857.
19. Miles KA, Griffiths MR. Perfusion CT: a worth while enhancement? Br J Radiol 2003; 76: 220-231.
20. García-Figueiras R, Goh VJ, Padhani AR, et al. CT perfusion in oncologic imaging: a useful tool? AJR Am J Roentgenol 2013; 200: 8-19.
21. Chen Y, Zhang J, Dai J, et al. Angiogenesis of renal cell carcinoma: perfusion CT findings. Abdom Imaging 2010; 35: 622-628.
22. Kambadakone AR, Sahani DV. Body perfusion CT: technique, clinical applications, and advances. Radiol Clin North Am 2009; 47: 161-178.
23. Harvey CJ, Blomley MJ, Dawson P. Functional CT imaging of the acute hyperemic response to radiation therapy of the prostate gland: early experience. J Comput Assist Tomogr 2001; 25: 43-49.
24. Schlemmer HP, Merkle J, Grobholz R, et al. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004; 14: 309-317.
25. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 2002; 94: 883-893.
26. Goh V, Halligan S, Daley F, et al. Colorectal tumor vascularity: quantitative assessment with multidetector CT – do tumor perfusion measurements. Radiology 2008; 249: 510-517.
27. Izawa JI, Dinney CP. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ 2001; 164: 662-670.
28. Strohmeyer D, Rössing C, Strauss F, et al. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000; 42: 26-33.
29. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998; 51: 161-167.
30. Łuczyńska E, Gasińska A, Wilk W. Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer. Pol J Pathol 2013; 64: 33-38.